Figure 1.

Expression of p16^INK4a is higher among cancer survivors compared with age‐matched, cancer‐free young adults. (A) This is a cross‐sectional comparison of p16 expression between young adult controls (n = 29; mean p16 expression, 8.9 log₂ units) and young adult cancer survivors (n = 60; mean p16 expression, 9.6 log₂ units). The mean age for both groups was 21 years. All survivors received an anthracycline/anthracenedione, an alkylator, or both as part of their treatment. (B) Distribution demonstrates expression levels of p16 in the survivor (orange dots) and control (black dots) cohorts by chronological age.